Literature DB >> 26022217

Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.

Pamela Thompson1, Vani Lakshminarayanan, Nitin T Supekar, Judy M Bradley, Peter A Cohen, Margreet A Wolfert, Sandra J Gendler, Geert-Jan Boons.   

Abstract

A strategy for the linear synthesis of a sialylated glycolipopeptide cancer vaccine candidate has been developed using a strategically designed sialyl-Tn building block and microwave-assisted solid-phase peptide synthesis. The glycolipopeptide elicited potent humoral and cellular immune responses. T-cells primed by such a vaccine candidate could be restimulated by tumor-associated MUC1.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26022217      PMCID： PMC4486256          DOI： 10.1039/c5cc02199e

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  45 in total

1.  Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine.

Authors:  Olivier Renaudet; Lbachir BenMohamed; Gargi Dasgupta; Ilham Bettahi; Pascal Dumy
Journal:  ChemMedChem       Date:  2008-05       Impact factor: 3.466

Review 2.  Structure and function of the cell surface (tethered) mucins.

Authors:  Christine L Hattrup; Sandra J Gendler
Journal:  Annu Rev Physiol       Date:  2008       Impact factor: 19.318

Review 3.  Advances in automatic, manual and microwave-assisted solid-phase peptide synthesis.

Authors:  Giuseppina Sabatino; Anna M Papini
Journal:  Curr Opin Drug Discov Devel       Date:  2008-11

4.  A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.

Authors:  Anton Kaiser; Nikola Gaidzik; Ulrika Westerlind; Danuta Kowalczyk; Alexandra Hobel; Edgar Schmitt; Horst Kunz
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

5.  Glycopeptide-specific monoclonal antibodies suggest new roles for O-GlcNAc.

Authors:  Chin Fen Teo; Sampat Ingale; Margreet A Wolfert; Galal A Elsayed; Laszlo G Nöt; John C Chatham; Lance Wells; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2010-03-21       Impact factor: 15.040

Review 6.  Mucin-type O-glycosylation and its potential use in drug and vaccine development.

Authors:  Mads Agervig Tarp; Henrik Clausen
Journal:  Biochim Biophys Acta       Date:  2007-09-25

7.  Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.

Authors:  Sampat Ingale; Margreet A Wolfert; Therese Buskas; Geert-Jan Boons
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

Review 8.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

9.  The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Authors:  Martin A Cheever; James P Allison; Andrea S Ferris; Olivera J Finn; Benjamin M Hastings; Toby T Hecht; Ira Mellman; Sheila A Prindiville; Jaye L Viner; Louis M Weiner; Lynn M Matrisian
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

10.  Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model.

Authors:  S Julien; G Picco; R Sewell; A-S Vercoutter-Edouart; M Tarp; D Miles; H Clausen; J Taylor-Papadimitriou; J M Burchell
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640
View more
  17 in total

Review 1.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

2.  Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Authors:  Nitin T Supekar; Vani Lakshminarayanan; Chantelle J Capicciotti; Anju Sirohiwal; Cathy S Madsen; Margreet A Wolfert; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Chembiochem       Date:  2017-11-30       Impact factor: 3.164

3.  Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen.

Authors:  Mohammadreza Movahedin; Teresa M Brooks; Nitin T Supekar; Naveen Gokanapudi; Geert-Jan Boons; Cory L Brooks
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

4.  Precise immunological evaluation rationalizes the design of a self-adjuvanting vaccine composed of glycan antigen, TLR1/2 ligand, and T-helper cell epitope.

Authors:  Tsung-Che Chang; Yoshiyuki Manabe; Keita Ito; Ryuku Yamamoto; Kazuya Kabayama; Shino Ohshima; Yoshie Kametani; Yukari Fujimoto; Chun-Cheng Lin; Koichi Fukase
Journal:  RSC Adv       Date:  2022-06-29       Impact factor: 4.036

Review 5.  Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines.

Authors:  Zhenyuan Wang; Chunjun Qin; Jing Hu; Xiaoqiang Guo; Jian Yin
Journal:  Virol Sin       Date:  2016-03-17       Impact factor: 4.327

6.  Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.

Authors:  Xuanjun Wu; Craig McKay; Christian Pett; Jin Yu; Manuel Schorlemer; Sherif Ramadan; Shuyao Lang; Sandra Behren; Ulrika Westerlind; M G Finn; Xuefei Huang
Journal:  ACS Chem Biol       Date:  2019-09-19       Impact factor: 5.100

7.  Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.

Authors:  Hui Cai; Jared Orwenyo; John P Giddens; Qiang Yang; Roushu Zhang; Celia C LaBranche; David C Montefiori; Lai-Xi Wang
Journal:  Cell Chem Biol       Date:  2017-10-26       Impact factor: 8.116

Review 8.  Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines.

Authors:  Md Kamal Hossain; Katherine A Wall
Journal:  Vaccines (Basel)       Date:  2016-07-26

Review 9.  Synthetic self-adjuvanting glycopeptide cancer vaccines.

Authors:  David M McDonald; Scott N Byrne; Richard J Payne
Journal:  Front Chem       Date:  2015-10-23       Impact factor: 5.221

10.  Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.

Authors:  Latha B Pathangey; Vani Lakshminarayanan; Vera J Suman; Barbara A Pockaj; Pinku Mukherjee; Sandra J Gendler
Journal:  Biomolecules       Date:  2016-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.